Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial
<i>Objective:</i> We aimed to evaluate the efficacy of the combination of atorvastatin and N-acetyl cysteine in increasing platelet counts in patients with immune thrombocytopenia who were resistant to steroid therapy or had a relapse after treatment. <i>Material and Methods</i&...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/59/6/1122 |
| _version_ | 1797593621157904384 |
|---|---|
| author | Lorena A Cervantes-Pérez Gabino Cervantes-Guevara Enrique Cervantes-Pérez Guillermo Alonso Cervantes-Cardona Adriana Nápoles-Echauri Alejandro González-Ojeda Clotilde Fuentes-Orozco Gabino Cervantes-Pérez Carlos A Reyes-Torres Francisco Javier Hernández-Mora Ana Lucia Ron-Magaña Janet Cristina Vázquez-Beltrán María Isabel Hernández-Rivas Sol Ramírez-Ochoa |
| author_facet | Lorena A Cervantes-Pérez Gabino Cervantes-Guevara Enrique Cervantes-Pérez Guillermo Alonso Cervantes-Cardona Adriana Nápoles-Echauri Alejandro González-Ojeda Clotilde Fuentes-Orozco Gabino Cervantes-Pérez Carlos A Reyes-Torres Francisco Javier Hernández-Mora Ana Lucia Ron-Magaña Janet Cristina Vázquez-Beltrán María Isabel Hernández-Rivas Sol Ramírez-Ochoa |
| author_sort | Lorena A Cervantes-Pérez |
| collection | DOAJ |
| description | <i>Objective:</i> We aimed to evaluate the efficacy of the combination of atorvastatin and N-acetyl cysteine in increasing platelet counts in patients with immune thrombocytopenia who were resistant to steroid therapy or had a relapse after treatment. <i>Material and Methods</i>: The patients included in this study received oral treatment of atorvastatin at a dose of 40 mg daily and N-acetyl cysteine at a dose of 400 mg every 8 h. The desired treatment duration was 12 months, but we included patients who completed at least 1 month of treatment in the analysis. The platelet counts were measured prior to the administration of the study treatment and in the first, third, sixth, and twelfth months of treatment (if available). A <i>p</i> value < 0.05 was considered statistically significant. <i>Results</i>: We included 15 patients who met our inclusion criteria. For the total treatment duration, the global response was 60% (nine patients); eight patients (53.3%) had a complete response and one patient (6.7%) had a partial response. Six patients (40%) were considered as having undergone treatment failure. Of the responder group, five patients maintained a complete response after treatment (55.5%), three patients maintained a partial response (33.3%), and one patient (11.1%) lost their response to the treatment. All of the patients in the responder group had significant increases in their platelet counts after treatment (<i>p</i> < 0.05). <i>Conclusion</i>: This study provides evidence of a possible treatment option for patients with primary immune thrombocytopenia. However, further studies are needed. |
| first_indexed | 2024-03-11T02:11:55Z |
| format | Article |
| id | doaj.art-ed1e1890038c4e7b95925de85ec42b7f |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-11T02:11:55Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-ed1e1890038c4e7b95925de85ec42b7f2023-11-18T11:31:47ZengMDPI AGMedicina1010-660X1648-91442023-06-01596112210.3390/medicina59061122Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical TrialLorena A Cervantes-Pérez0Gabino Cervantes-Guevara1Enrique Cervantes-Pérez2Guillermo Alonso Cervantes-Cardona3Adriana Nápoles-Echauri4Alejandro González-Ojeda5Clotilde Fuentes-Orozco6Gabino Cervantes-Pérez7Carlos A Reyes-Torres8Francisco Javier Hernández-Mora9Ana Lucia Ron-Magaña10Janet Cristina Vázquez-Beltrán11María Isabel Hernández-Rivas12Sol Ramírez-Ochoa13Department of Hematology, Hospital Civil de Guadalajaras “Fray Antonio Alcalde”, Guadalajara 44280,, MexicoDepartment of Welfare and Sustainable Development, Centro Universitario del Norte, Universidad de Guadalajara, Colotlán 46200, MexicoDepartment of Internal Medicine, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, MexicoDepartment of Philosophical, Methodological and Instrumental Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, MexicoDepartment of Philosophical, Methodological and Instrumental Disciplines, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, MexicoBiomedical Research Unit 02, Specialties Hospital of the Western National Medical Center, Mexican Institute of Social Security, Guadalajara 44329, MexicoBiomedical Research Unit 02, Specialties Hospital of the Western National Medical Center, Mexican Institute of Social Security, Guadalajara 44329, MexicoDepartment of Internal Medicine, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, MexicoSchool of Health Sciences, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico City 14380, MexicoHuman Reproduction, Growth and Child Development Clinic, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44340, MexicoDepartment of Hematology, Hospital Civil de Guadalajaras “Fray Antonio Alcalde”, Guadalajara 44280,, MexicoSchool of Medicine, Instituto Politécnico Nacional, Mexico City 11340, MexicoDepartament of Odontology for the Preservation of Health, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, MexicoDepartment of Internal Medicine, Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Health Sciences University Center, Universidad de Guadalajara, Guadalajara 44280, Mexico<i>Objective:</i> We aimed to evaluate the efficacy of the combination of atorvastatin and N-acetyl cysteine in increasing platelet counts in patients with immune thrombocytopenia who were resistant to steroid therapy or had a relapse after treatment. <i>Material and Methods</i>: The patients included in this study received oral treatment of atorvastatin at a dose of 40 mg daily and N-acetyl cysteine at a dose of 400 mg every 8 h. The desired treatment duration was 12 months, but we included patients who completed at least 1 month of treatment in the analysis. The platelet counts were measured prior to the administration of the study treatment and in the first, third, sixth, and twelfth months of treatment (if available). A <i>p</i> value < 0.05 was considered statistically significant. <i>Results</i>: We included 15 patients who met our inclusion criteria. For the total treatment duration, the global response was 60% (nine patients); eight patients (53.3%) had a complete response and one patient (6.7%) had a partial response. Six patients (40%) were considered as having undergone treatment failure. Of the responder group, five patients maintained a complete response after treatment (55.5%), three patients maintained a partial response (33.3%), and one patient (11.1%) lost their response to the treatment. All of the patients in the responder group had significant increases in their platelet counts after treatment (<i>p</i> < 0.05). <i>Conclusion</i>: This study provides evidence of a possible treatment option for patients with primary immune thrombocytopenia. However, further studies are needed.https://www.mdpi.com/1648-9144/59/6/1122immune thrombocytopeniaatorvastatinsteroidsN-acetyl cysteine |
| spellingShingle | Lorena A Cervantes-Pérez Gabino Cervantes-Guevara Enrique Cervantes-Pérez Guillermo Alonso Cervantes-Cardona Adriana Nápoles-Echauri Alejandro González-Ojeda Clotilde Fuentes-Orozco Gabino Cervantes-Pérez Carlos A Reyes-Torres Francisco Javier Hernández-Mora Ana Lucia Ron-Magaña Janet Cristina Vázquez-Beltrán María Isabel Hernández-Rivas Sol Ramírez-Ochoa Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial Medicina immune thrombocytopenia atorvastatin steroids N-acetyl cysteine |
| title | Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial |
| title_full | Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial |
| title_fullStr | Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial |
| title_full_unstemmed | Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial |
| title_short | Evaluation of the Effects of Atorvastatin and N-Acetyl Cysteine on Platelet Counts in Patients with Primary Immune Thrombocytopenia: An Exploratory Clinical Trial |
| title_sort | evaluation of the effects of atorvastatin and n acetyl cysteine on platelet counts in patients with primary immune thrombocytopenia an exploratory clinical trial |
| topic | immune thrombocytopenia atorvastatin steroids N-acetyl cysteine |
| url | https://www.mdpi.com/1648-9144/59/6/1122 |
| work_keys_str_mv | AT lorenaacervantesperez evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT gabinocervantesguevara evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT enriquecervantesperez evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT guillermoalonsocervantescardona evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT adriananapolesechauri evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT alejandrogonzalezojeda evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT clotildefuentesorozco evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT gabinocervantesperez evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT carlosareyestorres evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT franciscojavierhernandezmora evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT analuciaronmagana evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT janetcristinavazquezbeltran evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT mariaisabelhernandezrivas evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial AT solramirezochoa evaluationoftheeffectsofatorvastatinandnacetylcysteineonplateletcountsinpatientswithprimaryimmunethrombocytopeniaanexploratoryclinicaltrial |